News - Merck & Co, Victrelis

Filter

Current filters:

Merck & CoVictrelis

Popular Filters

Medivir/J&J, Merck & Co and Bristol-Myers to present at Int Liver Congress

09-04-2013

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) and US partner Johnson & Johnson (NYSE:…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirJohnson & JohnsonMedivirMerck & CoMK-5172PharmaceuticalResearchsimeprevirVaniprevirVictrelis

Australia to subsidize groundbreaking hepatitis C drugs under PBS

19-02-2013

The Australian government said on February 19 that it is extended subsidies of important medicines each…

Anti-viralsAsia-PacificFinancialHealthcareIncivoJohnson & JohnsonMerck & CoPharmaceuticalPricingVictrelis

Incivek and Victrelis important advances in HCV, but still unmet needs

20-06-2012

Nearly two-thirds of US surveyed physicians have seen an increase in the hepatitis C (HCV) patients they…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Incivek and Victrelis have collectively penetrated over three-quarters of the US genotype 1 HCV market

07-06-2012

One year post launch, Vertex's (Nasdaq: VRTX) Incivek (telaprevir) and Merck & Co (NYSE: MRK) and Roche's…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Incivek versus Victrelis in hepatitis C virus treatment: US physician views

10-04-2012

For the treatment of hepatitis C virus (HCV), the majority of surveyed US physicians survey by advisory…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

NICE backs Merck & Co hep C drug Victrelis

09-03-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has today (March 9)…

Anti-viralsEuropeMerck & CoPharmaceuticalPricingRegulationVictrelis

EMA recommends new Rxing info on Victrelis and warnings for aliskiren

20-02-2012

The European Medicines Agency has recommended updating the prescribing information for US drug giant…

Aliskiren TabletsAnti-viralsCardio-vascularEuropeMerck & CoNovartisPharmaceuticalRasilezRegulationTekturnaVictrelis

Dendreon cashes in Victrelis royalty

08-12-2011

US pharma company Dendreon (Nasdaq: DNDN) says that it has agreed to sell for $125 million in cash its…

Anti-viralsBiotechnologyDendreonFinancialLicensingMerck & CoOncologyPharmaceuticalProvengeVictrelis

Hepatitis C drug market in Mexico expected to double to $104 million in 2015

21-11-2011

The hepatitis C virus (HCV) market in Mexico will nearly double from $56 million in 2010 to $104 million…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalRocheSouth AmericaVertexVictrelis

Hepatitis C landscape changing as the new protease inhibitors adopted into clinical practice

09-10-2011

Three months after the launch of Vertex’ Incivek (telaprevir) and Merck & Co/Roche’s Victrelis…

IncivekMarkets & MarketingMerck & CoPharmaceuticalRocheVertexVictrelis

Launch trends for Incivek and Victrelis in hepatitis C sector

09-08-2011

Results from a survey fielded one month after the launch of Vertex’ (Nasdaq: VRTX) Incivek (telaprevir)…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalVertexVictrelis

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top